Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Altered circulating levels of matrix metalloproteinases and inhibitors associated with elevated type 2 cytokines in lymphatic filarial disease.

Anuradha R, George JP, Pavankumar N, Kumaraswami V, Nutman TB, Babu S.

PLoS Negl Trop Dis. 2012;6(6):e1681. doi: 10.1371/journal.pntd.0001681. Epub 2012 Jun 5.

2.

An alternate perspective on the roles of TIMPs and MMPs in pathology.

Moore CS, Crocker SJ.

Am J Pathol. 2012 Jan;180(1):12-6. doi: 10.1016/j.ajpath.2011.09.008. Epub 2011 Oct 25. Review.

PMID:
22033229
3.

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.

Bourboulia D, Stetler-Stevenson WG.

Semin Cancer Biol. 2010 Jun;20(3):161-8. doi: 10.1016/j.semcancer.2010.05.002. Epub 2010 May 12. Review.

4.
5.

Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases.

Gueders MM, Foidart JM, Noel A, Cataldo DD.

Eur J Pharmacol. 2006 Mar 8;533(1-3):133-44. Epub 2006 Feb 20. Review.

6.

Ovarian tissue remodeling: role of matrix metalloproteinases and their inhibitors.

Smith MF, Ricke WA, Bakke LJ, Dow MP, Smith GW.

Mol Cell Endocrinol. 2002 May 31;191(1):45-56. Review.

PMID:
12044918
7.

Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review).

Consolo M, Amoroso A, Spandidos DA, Mazzarino MC.

Int J Mol Med. 2009 Aug;24(2):143-52. Review.

PMID:
19578787
8.
9.

TIMPs as multifacial proteins.

Lambert E, Dassé E, Haye B, Petitfrère E.

Crit Rev Oncol Hematol. 2004 Mar;49(3):187-98. Review.

PMID:
15036259
10.

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).

Łukaszewicz-Zając M, Mroczko B, Słowik A.

J Neural Transm (Vienna). 2014 Nov;121(11):1387-97. doi: 10.1007/s00702-014-1205-3. Epub 2014 Jul 22. Review.

11.

Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral disease.

Verstappen J, Von den Hoff JW.

J Dent Res. 2006 Dec;85(12):1074-84. Review.

PMID:
17122157
12.

Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications.

Karthikeyan VJ, Lane DA, Beevers DG, Lip GY, Blann AD.

J Hum Hypertens. 2013 Feb;27(2):72-8. doi: 10.1038/jhh.2012.8. Epub 2012 Mar 15. Review.

PMID:
22418748
13.

Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.

Briasoulis A, Tousoulis D, Papageorgiou N, Kampoli AM, Androulakis E, Antoniades C, Tsiamis E, Latsios G, Stefanadis C.

Curr Top Med Chem. 2012;12(10):1214-21. Review.

PMID:
22519451
14.

The role of TIMPs in regulation of extracellular matrix proteolysis.

Arpino V, Brock M, Gill SE.

Matrix Biol. 2015 May-Jul;44-46:247-54. doi: 10.1016/j.matbio.2015.03.005. Epub 2015 Mar 21. Review.

15.

Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors.

Snoek-van Beurden PA, Von den Hoff JW.

Biotechniques. 2005 Jan;38(1):73-83. Review.

16.
17.

Matrix metalloproteinases: their biological functions and clinical implications.

Hijova E.

Bratisl Lek Listy. 2005;106(3):127-32. Review.

PMID:
16026148
18.

Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies.

Hemmann S, Graf J, Roderfeld M, Roeb E.

J Hepatol. 2007 May;46(5):955-75. Epub 2007 Mar 5. Review.

PMID:
17383048
19.

The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study.

Mroczko B, Groblewska M, Barcikowska M.

J Alzheimers Dis. 2013;37(2):273-83. doi: 10.3233/JAD-130647. Review.

PMID:
23792694
20.

Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.

Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ.

Clin Chem Lab Med. 2004 Feb;42(2):121-31. Review.

PMID:
15061349

Supplemental Content

Support Center